Literature DB >> 31698631

Mathematical investigation of HBeAg seroclearance.

Sarah Kadelka1, Stanca M Ciupe1.   

Abstract

Spontaneous or drug-induced loss of hepatitis B e antigen is considered a beneficial event in the disease progression of chronic hepatitis B virus infections. Mathematical models of within-host interactions are proposed; which provide insight into hepatitis B e antibody formation, its influence on hepatitis B e antigen seroclearance, and reversion of anergic cytotoxic immune responses. They predict that antibody expansion causes immune activation and hepatitis B e antigen seroclearance. Quantification of the time between antibody expansion and hepatitis B e antigen seroclearance in the presence and absence of treatment shows that potent short-term treatment speeds up the time between antibody expansion and hepatitis B e antigen seroclearance. The monthly hepatocyte turnover during this time can be increased or decreased by treatment depending on the amount of core promoter or precore mutated virus produced. The results can inform human interventions.

Entities:  

Keywords:  HBeAb ; mathematical modeling ; dHBeAg ; hepatitis B ; seroclearance

Year:  2019        PMID: 31698631     DOI: 10.3934/mbe.2019382

Source DB:  PubMed          Journal:  Math Biosci Eng        ISSN: 1547-1063            Impact factor:   2.080


  3 in total

1.  Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss.

Authors:  Yan Xue; Meng Zhang; Tao Li; Feng Liu; Li-Xin Zhang; Xiao-Ping Fan; Bao-Hua Yang; Lei Wang
Journal:  World J Gastroenterol       Date:  2021-04-14       Impact factor: 5.742

2.  Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infection.

Authors:  Sarah Kadelka; Harel Dahari; Stanca M Ciupe
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

3.  Early events in hepatitis B infection: the role of inoculum dose.

Authors:  Stanca M Ciupe; Naveen K Vaidya; Jonathan E Forde
Journal:  Proc Biol Sci       Date:  2021-02-10       Impact factor: 5.349

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.